Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
Angelos Stergiou, Anavex’s Vice President, Clinical Development & Medical Affairs. Conference Call Management will host a live investor conference call on Wednesday, March 16, 2011 at A recorded version of the call will be posted on our web site shortly after the call. About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Dr. Jeffrey Cummings to its Scientific Advisory Board
About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Independent Director
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Dr. Rachelle Doody to Scientific Advisory Board
available, FDA-approved drugs for Alzheimer’s disease, and was the lead site for the development of the most About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Adds Dr. Paul Aisen to Scientific Advisory Board
About Alzheimer’s While Alzheimer’s is most common in people over the age of 65, it can strike adults Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law
I clinical trial in humans, ANAVEX 2-73 was recently chosen by Alzheimer’s Weekly as the number one most About Alzheimer’s While Alzheimer’s is most common in people over the age of 65, it can strike adults modulation of multiple cellular biochemical signaling pathways. [1] Noted in a recent research article (http Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease
(“Anavex”, AVXL.OB) announced today that ANAVEX 2-73 has been named 2010’s “most promising trial drug The full Alzheimer’s Weekly article is available here: http://www.AlzWeek.com/node/970. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints David Tousley as CFO
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data
receptor/sigma 1 ligand ANAVEX 2-73, a novel aminotetrahydrofuran derivative”, is available online at http Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free:1-866-
- Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring in the Pharmaceutical Industry
the company’s Executive Chairman, has been named in this year’s “PharmaVOICE 100” as one of the 100 most A link to the online edition is available in the media section. Durrant’s expert profile may be viewed from the media section. About ANAVEX Life Sciences Corp. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs
Exploratory biomarkers, pre- / post- neuronal glucose consumption, and comprehensive psychometric test development to accelerate approval timelines and maximize the value of a pharmaceutical, biologic or medical Local CRAs and regulatory expertise ensure fast study set-up and efficient monitoring. multicenter studies, pharmacodynamic phase I studies, including for biologicals, radiopharmaceuticals, and HTPs Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free:1-866-
